Bottom line
XLV vs HGHAX: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and HGHAX (The Hartford Healthcare Fund) share a meaningful slice of their top holdings — about 72% by weight.
XLV is cheaper at 0.08% vs 1.33% — a difference of $125 a year per $10,000 invested.
HGHAX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
XLV vs HGHAX side by side
| XLV | HGHAX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | SPDR (State Street) | Hartford |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 1.33% |
| Annual cost per $10k | $8 | $133 |
| 10-yr cost on $10k (prospectus) | $103 | $2,063 |
| Max front load | None | 5.5% |
| 12b-1 fee | 0.02% | 0.25% |
| 1-yr return | +14.5% | — |
| 5-yr return (annualized) | +8.1% | — |
| 10-yr return (annualized) | +9.8% | — |
| Best quarter | +14.5% | +20.9% |
| Worst quarter | −12.7% | −15.7% |
| Net assets (fund) | $40.6B | $772.2M |
| Number of holdings | 65 | 80 |
| Portfolio turnover | 2% | 49% |
| Returns as of | Dec 31, 2025 | — |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | HGHAX | Difference |
|---|---|---|---|
| 2025 | +14.5% | +15.6% | −1.1% |
| 2024 | +2.5% | 0.0% | +2.5% |
| 2023 | +2.0% | +3.8% | −1.8% |
| 2022 | −2.1% | −11.7% | +9.7% |
| 2021 | +25.9% | +10.0% | +16.0% |
| 2020 | +13.3% | +22.6% | −9.3% |
| 2019 | +20.7% | +33.3% | −12.6% |
| 2018 | +6.3% | −3.0% | +9.3% |
| 2017 | +21.7% | +21.6% | +0.1% |
| 2016 | −2.8% | −8.6% | +5.7% |
Source: Fund prospectus bar charts
Holdings overlap
19 of XLV's top 25 holdings also appear in HGHAX's top 25.
| Holding | XLV | HGHAX |
|---|---|---|
| Eli Lilly & Co | 16.51% | 12.03% |
| Johnson & Johnson | 10.64% | 6.75% |
| AbbVie Inc | 7.74% | 4.21% |
| UnitedHealth Group Inc | 6.57% | 4.74% |
| Merck & Co Inc | 5.52% | 6.00% |
| Amgen Inc | 3.40% | 1.39% |
| Thermo Fisher Scientific Inc | 3.24% | 1.58% |
| Abbott Laboratories | 2.75% | 1.82% |
| Intuitive Surgical Inc | 2.45% | 2.88% |
| CVS Health Corp | 2.30% | 2.84% |
| Vertex Pharmaceuticals Inc | 2.19% | 2.64% |
| Danaher Corp | 2.09% | 2.57% |
| Stryker Corp | 1.89% | 1.24% |
| Medtronic PLC | 1.75% | 1.12% |
| Elevance Health Inc | 1.46% | 3.00% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
HGHAX top 10
- Eli Lilly & Co — 12.03%
- Johnson & Johnson — 6.75%
- Merck & Co Inc — 6.00%
- UnitedHealth Group Inc — 4.74%
- AbbVie Inc — 4.21%
- Elevance Health Inc — 3.00%
- Intuitive Surgical Inc — 2.88%
- CVS Health Corp — 2.84%
- Vertex Pharmaceuticals Inc — 2.64%
- Danaher Corp — 2.57%
FAQ
What is the difference between XLV and HGHAX?
Which is cheaper, XLV or HGHAX?
Should I own both XLV and HGHAX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.